KERLEDEX
LOE ApproachingNDAORALTABLET
Approved
Oct 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KERLEDEX is an oral small-molecule tablet approved by Sanofi in 1992 for an undisclosed indication. The drug's mechanism of action and specific therapeutic target remain unknown from available data.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting contracted commercial teams and defensive portfolio positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect KERLEDEX's mature, contraction-phase status. Career opportunities center on cost management, market defense, and transition planning rather than growth initiatives.
Brand Manager (Defensive)Field Sales
Worked on KERLEDEX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.